Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710089 | 0.95 | CYP1A2 (0.56) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16710100 | 0.93 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16706675 | 0.92 | RAB9A (0.54) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16706696 | 0.91 | MMP13 (0.58) | SMN1; SMN2ALDH1A1HPGDMAPK1MEN1 | |
| SCHEMBL16706674 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16706698 | 0.89 | MMP13 (0.58) | SMN1; SMN2ALDH1A1HPGDMAPK1MEN1 | |
| SCHEMBL16710031 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16710128 | 0.89 | HPGD (0.53) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18939745 | 0.88 | RAB9A (0.48) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16706776 | 0.88 | MMP13 (0.61) | SMN1; SMN2ALDH1A1HPGDMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | SMN1; SMN2 2862/4885CYP1A2 2116/4885CYP3A4 4245/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | SMN1; SMN2 3065/4885CYP1A2 2050/4885CYP3A4 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.